Lipid nanoparticle delivery of a microRNA-145 inhibitor improves experimental pulmonary hypertension

Journal of Controlled Release

Volumn 210, Issue , 2015, Pages 67-75

  McLendon, Jared M ^a,b   Joshi, Sachindra R ^a,b   Sparks, Jeff ^c   Matar, Majed ^c   Fewell, Jason G ^c   Abe, Kohtaro ^b   Oka, Masahiko ^b   McMurtry, Ivan F ^b   Gerthoffer, William T ^a,b  

^a UNIVERSITY OF SOUTH ALABAMA   (United States)

^b UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE   (United States)

^c EGEN Inc   (United States)

Author keywords

Antisense oligonucleotide; Lipid nanoparticle; Lung delivery; MicroRNA 145; Pulmonary hypertension; Sugen5416 hypoxia

Indexed keywords

BIOLOGICAL ORGANS; CELL PROLIFERATION; CELLS; CYTOLOGY; DISEASE CONTROL; GENE EXPRESSION; MOTION PICTURE EXPERTS GROUP STANDARDS; NANOPARTICLES; OLIGONUCLEOTIDES; RATS; REPAIR; STARS; TOXICITY;

ANTISENSE OLIGONUCLEOTIDES; LIPID NANOPARTICLES; LUNG DELIVERIES; MICRORNAS; PULMONARY HYPERTENSION; SUGEN5416/HYPOXIA;

RNA;

ANTISENSE OLIGONUCLEOTIDE; LIPID; LIPOPOLYAMINE NANOPARTICLE; MACROGOL; MICRORNA 145; NANOPARTICLE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; INDOLE DERIVATIVE; LIPOSOME; LOCKED NUCLEIC ACID; MICRORNA; OLIGONUCLEOTIDE; PYRROLE DERIVATIVE; SEMAXANIB;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTISENSE THERAPY; ARTICLE; BLOOD CELL COUNT; CELL FATE; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; EXPERIMENTAL PULMONARY HYPERTENSION; GENE EXPRESSION; HEART FUNCTION; HISTOPATHOLOGY; IN SITU HYBRIDIZATION; IN VIVO STUDY; KIDNEY; LEUKOCYTE; LIVER; LUNG PARENCHYMA; MALE; NONHUMAN; ORGAN DISTRIBUTION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PULMONARY VASCULAR DISEASE; RAT; RNA INTERFERENCE; SPLEEN; TARGET CELL; THERAPY EFFECT; TOXICITY TESTING; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; COMPLICATION; HYPERTENSION, PULMONARY; HYPOXIA; LUNG; METABOLISM; SPRAGUE DAWLEY RAT;

ANIMALS; HYPERTENSION, PULMONARY; HYPOXIA; INDOLES; LIPIDS; LIPOSOMES; LUNG; MALE; MICRORNAS; NANOPARTICLES; OLIGONUCLEOTIDES; PYRROLES; RATS, SPRAGUE-DAWLEY;

EID: 84929649428     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2015.05.261     Document Type: Article

References (44)

1. N.F. Voelkel Right ventricular function and failure: report of a National Heart, Lung, and Blood Institute working group on cellular and molecular mechanisms of right heart failure Circulation 114 17 2006 1883 1891
2. S.Y. Chan, and J. Loscalzo Pathogenic mechanisms of pulmonary arterial hypertension J. Mol. Cell. Cardiol. 44 1 2008 14 30
3. M. Humbert Cellular and molecular pathobiology of pulmonary arterial hypertension J. Am. Coll. Cardiol. 43 12 Suppl S 2004 13S 24S
4. M. Rabinovitch Molecular pathogenesis of pulmonary arterial hypertension J. Clin. Invest. 118 7 2008 2372 2379
5. R.A. McDonald MicroRNA and vascular remodelling in acute vascular injury and pulmonary vascular remodelling Cardiovasc. Res. 93 4 2012 594 604
6. N.W. Morrell Cellular and molecular basis of pulmonary arterial hypertension J. Am. Coll. Cardiol. 54 1 Suppl 2009 S20 S31
7. P. Caruso Dynamic changes in lung microRNA profiles during the development of pulmonary hypertension due to chronic hypoxia and monocrotaline Arterioscler. Thromb. Vasc. Biol. 30 4 2010 716 723
8. P. Caruso A role for miR-145 in pulmonary arterial hypertension: evidence from mouse models and patient samples Circ. Res. 111 3 2012 290 300
9. A. Courboulin Role for miR-204 in human pulmonary arterial hypertension J. Exp. Med. 208 3 2011 535 548
10. S.S. Pullamsetti Inhibition of microRNA-17 improves lung and heart function in experimental pulmonary hypertension Am. J. Respir. Crit. Care Med. 185 4 2012 409 419
11. M. Brock AntagomiR directed against miR-20a restores functional BMPR2 signalling and prevents vascular remodelling in hypoxia-induced pulmonary hypertension Eur. Heart J. 35 45 2014 3203 3211
12. S. Yang miR-21 regulates chronic hypoxia-induced pulmonary vascular remodeling Am. J. Physiol. Lung Cell. Mol. Physiol. 302 6 2012 L521 L529
13. V.N. Parikh MicroRNA-21 integrates pathogenic signaling to control pulmonary hypertension: results of a network bioinformatics approach Circulation 125 12 2012 1520 1532
14. L. Guo The MicroRNA-328 Regulates Hypoxic Pulmonary Hypertension by Targeting at Insulin Growth Factor 1 Receptor and L-Type Calcium Channel-alpha1C Hypertension 59 5 2012 1006 1013
15. J. Kim An endothelial apelin-FGF link mediated by miR-424 and miR-503 is disrupted in pulmonary arterial hypertension Nat. Med. 19 1 2013 74 82
16. D. Haussecker Current issues of RNAi therapeutics delivery and development J. Control. Release 195 2014 49 54
17. K.J. Polach Delivery of siRNA to the mouse lung via a functionalized lipopolyamine Mol. Ther. 20 1 2012 91 100
18. J. Sparks Versatile cationic lipids for siRNA delivery J. Control. Release 158 2 2012 269 276
19. K.R. Cordes miR-145 and miR-143 regulate smooth muscle cell fate and plasticity Nature 460 7256 2009 705 710
20. Y. Cheng MicroRNA-145, a novel smooth muscle cell phenotypic marker and modulator, controls vascular neointimal lesion formation Circ. Res. 105 2 2009 158 166
21. S. Yamaguchi The role of microRNA-145 in human embryonic stem cell differentiation into vascular cells Atherosclerosis 219 2 2011 468 474
22. M. Xin MicroRNAs miR-143 and miR-145 modulate cytoskeletal dynamics and responsiveness of smooth muscle cells to injury Genes Dev. 23 18 2009 2166 2178
23. L. Elia The knockout of miR-143 and -145 alters smooth muscle cell maintenance and vascular homeostasis in mice: correlates with human disease Cell Death Differ. 16 12 2009 1590 1598
24. T. Boettger Acquisition of the contractile phenotype by murine arterial smooth muscle cells depends on the Mir143/145 gene cluster J. Clin. Invest. 119 9 2009 2634 2647
25. R. Hutcheson MicroRNA-145 restores contractile vascular smooth muscle phenotype and coronary collateral growth in the metabolic syndrome Arterioscler. Thromb. Vasc. Biol. 33 4 2013 727 736
26. N. Xu MicroRNA-145 regulates OCT4, SOX2, and KLF4 and represses pluripotency in human embryonic stem cells Cell 137 4 2009 647 658
27. M.M. Jared Targeted pulmonary delivery of a microRNA-145 inhibitor reverses severe pulmonary arterial hypertension in rats, in A97 The Role of MicroRNAs in Pulmonary Vascular Disease 2013 American Thoracic Society (A2093-A2093)
28. R.J. Sachindra Treatment with anti-microRNA-145 in an experimental model of occlusive pulmonary arterial hypertension reverses vascular remodeling, in A97 The Role of MicroRNAs in Pulmonary Vascular Disease 2013 American Thoracic Society (A2095-A2095)
29. K. Abe MicroRNA in hypoxia-induced pulmonary hypertension in rats Am. J. Respir. Crit. Care Med. 179 2009 A1851
30. L. Taraseviciene-Stewart Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension FASEB J. 15 2 2001 427 438
31. K. Abe Formation of plexiform lesions in experimental severe pulmonary arterial hypertension Circulation 121 25 2010 2747 2754
32. P. Pacher Measurement of cardiac function using pressure-volume conductance catheter technique in mice and rats Nat. Protoc. 3 9 2008 1422 1434
33. N. Hanasato E-4010, a selective phosphodiesterase 5 inhibitor, attenuates hypoxic pulmonary hypertension in rats Am. J. Physiol. 277 2 Pt 1 1999 L225 L232
34. A. Alzoubi Dehydroepiandrosterone restores right ventricular structure and function in rats with severe pulmonary arterial hypertension Am. J. Physiol. Heart Circ. Physiol. 304 12 2013 H1708 H1718
35. J.L. Faul Triptolide attenuates pulmonary arterial hypertension and neointimal formation in rats Am. J. Respir. Crit. Care Med. 162 6 2000 2252 2258
36. M. Toba Temporal hemodynamic and histological progression in Sugen5416/hypoxia/normoxia-exposed pulmonary arterial hypertensive rats Am. J. Physiol. Heart Circ. Physiol. 306 2 2014 H243 H250
37. S. Obad Silencing of microRNA families by seed-targeting tiny LNAs Nat. Genet. 43 4 2011 371 378
38. E.E. Swayze Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals Nucleic Acids Res. 35 2 2007 687 700
39. S.A. Barros, and J.A. Gollob Safety profile of RNAi nanomedicines Adv. Drug Deliv. Rev. 64 15 2012 1730 1737
40. M.E. Kleinman Sequence- and target-independent angiogenesis suppression by siRNA via TLR3 Nature 452 7187 2008 591 597
41. D. Urboniene Validation of high-resolution echocardiography and magnetic resonance imaging vs. high-fidelity catheterization in experimental pulmonary hypertension Am. J. Physiol. Lung Cell. Mol. Physiol. 299 3 2010 L401 L412
42. J.W. Koskenvuo A comparison of echocardiography to invasive measurement in the evaluation of pulmonary arterial hypertension in a rat model Int. J. Cardiovasc. Imaging 26 5 2010 509 518
43. T. Ryan An echocardiographic index for separation of right ventricular volume and pressure overload J. Am. Coll. Cardiol. 5 4 1985 918 927
44. Y.S. Wang Role of miR-145 in cardiac myofibroblast differentiation J. Mol. Cell. Cardiol. 66 2014 94 105